CJC-1295 DAC Peptide 2mg

CJC-1295 DAC Peptide 2mg: Product Overview

CJC-1295 DAC Peptide 2mg is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). Developed with Drug Affinity Complex (DAC) technology, CJC-1295 DAC has been investigated for its ability to stimulate endogenous growth hormone (GH) secretion and influence insulin-like growth factor 1 (IGF-1) signaling.

The defining characteristic of CJC-1295 with DAC is its albumin-binding modification, designed to prolong the compound's presence in circulation. This distinguishes CJC-1295 DAC from shorter-acting GHRH analogs and CJC-1295 formulations without DAC.

The 2mg designation identifies the stated quantity of peptide material in this product listing.

CJC-1295 DAC 2mg Product Specifications

• Product Name: CJC-1295 DAC Peptide 2mg
• Alternative Names: CJC-1295 with DAC, DAC:GRF
• Peptide Type: Synthetic modified GHRH analog
• Classification: Growth hormone-releasing hormone receptor agonist
• Drug Affinity Complex: Albumin-binding DAC modification
• Peptide Structure: 30 amino acid residues with a modified lysine linker
• CAS Number: 446262-90-4 (DAC free base)
• Molecular Formula: C165H269N47O46 (DAC free base)
• Molecular Weight: Approximately 3647.95 g/mol (DAC free base)
• Listed Quantity: 2mg
• Research Category: Growth Hormone and IGF-1 Signaling
• Product Category: Research Peptides

These specifications describe the CJC-1295 DAC free-base structure. Acetate or other salt forms can differ in composition. Product-specific analytical documentation should confirm the supplied molecular identity.

What Is CJC-1295 DAC Peptide?

CJC-1295 DAC is a modified analog of growth hormone-releasing hormone, a naturally occurring peptide involved in the regulation of pituitary growth hormone secretion.

The compound incorporates structural modifications intended to increase stability and extend its duration of activity. Its Drug Affinity Complex enables interaction with circulating albumin, a protein that can influence the pharmacokinetic behavior of associated compounds.

CJC-1295 DAC has been investigated in clinical pharmacology research involving growth hormone and IGF-1 responses, making it an important compound in studies of GHRH receptor signaling.

Key Characteristics of CJC-1295 DAC

• Long-Acting GHRH Analog: Developed to provide prolonged exposure compared with native GHRH.
• Drug Affinity Complex Technology: Incorporates an albumin-binding modification designed to influence peptide pharmacokinetics.
• Growth Hormone Signaling: Investigated for stimulation of endogenous GH secretion through GHRH receptor pathways.
• IGF-1 Research: Examined in studies measuring changes in circulating insulin-like growth factor 1.
• Distinct DAC Structure: Chemically different from CJC-1295 without DAC, also commonly called Modified GRF (1-29).
• 2mg Presentation: Defined peptide quantity for research documentation and catalog identification.

What Is Drug Affinity Complex (DAC) Technology?

Drug Affinity Complex technology is a molecular modification approach designed to extend the circulating lifetime of selected peptide compounds.

In CJC-1295 DAC, an albumin-reactive group is attached to a modified peptide structure. This modification allows the peptide to associate covalently with serum albumin, influencing its distribution and clearance.

Published human pharmacology research involving the DAC-containing compound reported an estimated elimination half-life of approximately 5.8 to 8.1 days under the conditions studied.

These pharmacokinetic findings describe the investigated compound and should not be interpreted as dosing guidance or evidence of equivalent performance for independently supplied products.

CJC-1295 DAC Mechanism of Action

CJC-1295 DAC acts through the growth hormone-releasing hormone receptor (GHRH-R), which participates in the regulation of growth hormone secretion from the anterior pituitary gland.

Activation of GHRH receptor signaling can stimulate endogenous GH release. Growth hormone, in turn, influences the production and regulation of insulin-like growth factor 1.

The DAC modification primarily affects the pharmacokinetic properties of the peptide rather than transforming it into recombinant growth hormone. CJC-1295 DAC remains a GHRH analog rather than a replacement for the HGH protein.

CJC-1295 DAC Research Background

CJC-1295 DAC has been investigated in controlled human pharmacology studies examining growth hormone secretion, IGF-1 responses, and duration of peptide activity.

Published investigations in healthy adults reported prolonged elevations in GH and IGF-1 following administration of the studied CJC-1295 compound. These findings established interest in its long-acting receptor-mediated activity.

However, these early studies were relatively small and primarily evaluated pharmacological endpoints. They do not establish clinical benefits for muscle growth, recovery, anti-aging, or treatment of growth hormone disorders.

Further controlled research would be required to determine long-term safety and clinical effectiveness for any proposed therapeutic application.

CJC-1295 DAC vs CJC-1295 Without DAC

CJC-1295 with DAC and CJC-1295 without DAC are frequently grouped together in peptide catalogs, but they represent structurally different preparations.

• CJC-1295 with DAC: Contains an albumin-binding chemical modification designed for prolonged peptide exposure.
• CJC-1295 without DAC: Commonly refers to Modified GRF (1-29), a related 29-amino-acid GHRH analog without the DAC linker.
• Primary Difference: The DAC modification changes molecular structure and pharmacokinetic behavior.
• Research Evidence: Published human pharmacokinetic findings for CJC-1295 DAC should not automatically be attributed to the non-DAC compound.

Because commercial naming conventions are sometimes inconsistent, identifying the exact peptide structure is especially important when evaluating CJC-1295 products.

CJC-1295 DAC vs Ipamorelin

CJC-1295 DAC and Ipamorelin are investigated in growth hormone-related research, but they activate different receptor systems.

• CJC-1295 DAC: A modified GHRH analog that acts through growth hormone-releasing hormone receptors.
• Ipamorelin: A synthetic pentapeptide that interacts with the growth hormone secretagogue receptor, also known as the ghrelin receptor GHS-R1a.
• Key Difference: The compounds have different molecular structures, receptor targets, and pharmacological profiles.

These differences are important when comparing experimental results. Neither compound should be considered interchangeable with the other or with recombinant human growth hormone.

CJC-1295 DAC vs Human Growth Hormone (HGH)

CJC-1295 DAC and recombinant human growth hormone are fundamentally different biological compounds.

CJC-1295 DAC is a synthetic GHRH receptor agonist investigated for its effects on endogenous hormone secretion. Recombinant HGH is a manufactured version of the complete human growth hormone protein.

These compounds differ in molecular structure, receptor interactions, pharmacokinetics, and research applications.

CJC-1295 DAC 2mg Product Documentation

The CJC-1295 DAC Peptide 2mg product listing identifies a stated 2mg quantity of peptide material.

Product evaluation should include the declared peptide identity, chemical form, presence of the DAC modification, and available batch-specific analytical documentation.

Additional information may include identity testing, purity analysis, peptide content, and formulation-specific storage instructions. General molecular reference specifications do not establish the composition or quality of an individual supplied batch.

CJC-1295 DAC remains an investigational compound. Its long-term safety and effectiveness for therapeutic or performance-related applications have not been established.